Celldex Therapeutics, Inc. (NASDAQ:CLDX) Shares Purchased by DNB Asset Management AS

DNB Asset Management AS raised its holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 47.2% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 7,872 shares of the biopharmaceutical company’s stock after acquiring an additional 2,523 shares during the quarter. DNB Asset Management AS’s holdings in Celldex Therapeutics were worth $292,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently bought and sold shares of CLDX. Wellington Management Group LLP lifted its position in shares of Celldex Therapeutics by 19.2% during the 4th quarter. Wellington Management Group LLP now owns 6,476,561 shares of the biopharmaceutical company’s stock valued at $256,860,000 after acquiring an additional 1,044,728 shares during the period. Vanguard Group Inc. raised its stake in shares of Celldex Therapeutics by 19.8% during the 1st quarter. Vanguard Group Inc. now owns 3,650,582 shares of the biopharmaceutical company’s stock worth $153,215,000 after buying an additional 604,251 shares during the last quarter. Eventide Asset Management LLC raised its stake in shares of Celldex Therapeutics by 126.9% during the 4th quarter. Eventide Asset Management LLC now owns 3,630,013 shares of the biopharmaceutical company’s stock worth $143,966,000 after buying an additional 2,030,013 shares during the last quarter. Price T Rowe Associates Inc. MD raised its stake in shares of Celldex Therapeutics by 631.1% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,087,208 shares of the biopharmaceutical company’s stock worth $129,571,000 after buying an additional 2,664,915 shares during the last quarter. Finally, Bellevue Group AG raised its stake in shares of Celldex Therapeutics by 15.7% during the 1st quarter. Bellevue Group AG now owns 2,796,615 shares of the biopharmaceutical company’s stock worth $117,374,000 after buying an additional 380,319 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on CLDX shares. Stifel Nicolaus started coverage on Celldex Therapeutics in a research report on Tuesday, June 18th. They set a “buy” rating and a $58.00 price objective for the company. Wolfe Research began coverage on Celldex Therapeutics in a research report on Tuesday, June 11th. They set an “outperform” rating and a $51.00 price objective for the company. Cantor Fitzgerald reissued an “overweight” rating and issued a $67.00 target price on shares of Celldex Therapeutics in a research note on Tuesday, July 30th. Finally, HC Wainwright reissued a “buy” rating and issued a $80.00 target price on shares of Celldex Therapeutics in a research note on Tuesday, July 30th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $62.17.

Insider Activity at Celldex Therapeutics

In other Celldex Therapeutics news, VP Elizabeth Crowley sold 38,597 shares of the company’s stock in a transaction dated Thursday, May 30th. The stock was sold at an average price of $33.64, for a total transaction of $1,298,403.08. Following the completion of the sale, the vice president now directly owns 9,074 shares in the company, valued at $305,249.36. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Celldex Therapeutics news, VP Elizabeth Crowley sold 38,597 shares of the business’s stock in a transaction that occurred on Thursday, May 30th. The shares were sold at an average price of $33.64, for a total transaction of $1,298,403.08. Following the completion of the sale, the vice president now directly owns 9,074 shares in the company, valued at $305,249.36. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Richard M. Wright sold 46,844 shares of the stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $33.72, for a total transaction of $1,579,579.68. Following the completion of the sale, the vice president now directly owns 20,833 shares of the company’s stock, valued at approximately $702,488.76. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 266,332 shares of company stock worth $9,155,821. 3.80% of the stock is owned by insiders.

Celldex Therapeutics Trading Up 0.8 %

Shares of NASDAQ CLDX traded up $0.28 on Wednesday, reaching $33.79. 16,617 shares of the company traded hands, compared to its average volume of 791,174. Celldex Therapeutics, Inc. has a fifty-two week low of $22.11 and a fifty-two week high of $53.18. The company has a 50 day moving average of $36.62 and a 200 day moving average of $38.98. The stock has a market capitalization of $2.23 billion, a PE ratio of -11.76 and a beta of 1.58.

Celldex Therapeutics (NASDAQ:CLDX) last posted its quarterly earnings data on Monday, May 6th. The biopharmaceutical company reported ($0.56) EPS for the quarter, beating analysts’ consensus estimates of ($0.67) by $0.11. The company had revenue of $0.16 million during the quarter, compared to the consensus estimate of $1.30 million. Celldex Therapeutics had a negative net margin of 2,385.57% and a negative return on equity of 29.55%. As a group, research analysts expect that Celldex Therapeutics, Inc. will post -2.39 earnings per share for the current year.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.